German biotech firm Tubulis has raised €308 million in a record-breaking Collection C funding spherical, marking the biggest Collection C ever closed by a European biotech and the largest financing for a non-public antibody-drug conjugate (ADC) developer worldwide. The spherical was led by Venrock Healthcare Capital Companions, with participation from Wellington Administration and Ascenta Capital, alongside current traders together with Nextech Make investments, EQT Life Sciences, Frazier Life Sciences, Andera Companions, Deep Observe Capital, Bayern Kapital, Fund+, OCCIDENT, Seventure Companions, and HTGF.
Based in Munich, Tubulis specialises in creating uniquely matched ADCs that mix antibodies with potent medicine to focus on and destroy most cancers cells with excessive precision. The brand new funding will speed up the medical improvement of its lead candidate, TUB-040, which targets NaPi2b, an antigen overexpressed in ovarian and lung cancers. At present beneath analysis in a Section I/IIa examine, TUB-040 obtained Quick Observe designation from the U.S. FDA in 2024.
The recent capital may even advance Tubulis’ broader pipeline, together with TUB-030 and a number of preclinical programmes, in addition to develop its proprietary ADC platform applied sciences. These improvements intention to unlock new therapeutic prospects and enhance outcomes for sufferers with stable tumours.
“This landmark financing spherical displays the deep conviction these world healthcare traders have in Tubulis and the disruptive potential of our ADC platforms,” mentioned Dr. Dominik Schumacher, CEO and Co-founder of Tubulis. “With TUB-040 progressing within the clinic and first knowledge to be shared in a late-breaking oral presentation at ESMO, we’re able to develop into earlier remedy traces, whereas persevering with to innovate throughout our pipeline and expertise platforms. The brand new funding empowers us to execute on our imaginative and prescient of making really differentiated antibody-drug conjugates which can be tailor-made to the biology of stable tumours and may ship superior therapeutic worth to sufferers.”
HTGF (Excessive-Tech Gründerfonds), one among Tubulis’ earliest backers, renewed and expanded its dedication on this spherical. The investor co-led Tubulis’ Collection A in 2020 and has supported the corporate from idea to medical improvement, underlining Germany’s power as a biotech innovation hub and its skill to mobilise non-public capital for capital-intensive applied sciences.
“HTGF was one among our earliest traders and supported us in shaping Tubulis throughout its childhood. Their renewed dedication on this spherical displays the continued partnership and shared perception in our mission to develop the therapeutic potential of ADCs for sufferers worldwide,” mentioned Dr. Dominik Schumacher, CEO and Co-founder of Tubulis.
Dr. Frank Hensel, Principal at HTGF, added: “Our relationship with Tubulis has at all times been constructed on belief and a shared ambition to redefine oncology remedy. This newest spherical, supported by main world traders, validates the power of the platform and the staff. We’re proud to proceed backing Tubulis because it enters a pivotal part of medical improvement.”
Dr. Achim Plum, Managing Director at HTGF, mentioned: “Tubulis’ Collection C demonstrates that even extremely capital-intensive, disruptive applied sciences can appeal to the non-public funding wanted to convey cutting-edge therapies to sufferers. For us at HTGF, Tubulis is a major instance of how we function: we interact very early, usually earlier than an organization is based, and construct trusted relationships with distinctive groups. This story displays our perception in scientific excellence, entrepreneurial imaginative and prescient, and the influence that may be achieved when each come collectively. Congratulations to your entire Tubulis staff on this excellent success.”
Tubulis’ breakthrough ADC applied sciences have positioned it as one among Europe’s most promising biotech gamers. By combining world-class science, medical progress, and world investor confidence, the corporate continues to advance its mission of increasing the therapeutic potential of ADCs for most cancers sufferers worldwide.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our e-newsletter, and be part of our rising group at nextbusiness24.com